1
|
Ghai RR, Straily A, Wineland N, Calogero J, Stobierski MG, Signs K, Blievernicht M, Torres-Mendoza Y, Waltenburg MA, Condrey JA, Blankenship HM, Riner D, Barr N, Schalow M, Goodrich J, Collins C, Ahmad A, Metz JM, Herzegh O, Straka K, Arsnoe DM, Duffiney AG, Shriner SA, Kainulainen MH, Carpenter A, Whitehill F, Wendling NM, Stoddard RA, Retchless AC, Uehara A, Tao Y, Li Y, Zhang J, Tong S, Barton Behravesh C. Epidemiologic and Genomic Evidence for Zoonotic Transmission of SARS-CoV-2 among People and Animals on a Michigan Mink Farm, United States, 2020. Viruses 2023; 15:2436. [PMID: 38140677 PMCID: PMC10747742 DOI: 10.3390/v15122436] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2023] [Revised: 12/07/2023] [Accepted: 12/08/2023] [Indexed: 12/24/2023] Open
Abstract
Farmed mink are one of few animals in which infection with SARS-CoV-2 has resulted in sustained transmission among a population and spillback from mink to people. In September 2020, mink on a Michigan farm exhibited increased morbidity and mortality rates due to confirmed SARS-CoV-2 infection. We conducted an epidemiologic investigation to identify the source of initial mink exposure, assess the degree of spread within the facility's overall mink population, and evaluate the risk of further viral spread on the farm and in surrounding wildlife habitats. Three farm employees reported symptoms consistent with COVID-19 the same day that increased mortality rates were observed among the mink herd. One of these individuals, and another asymptomatic employee, tested positive for SARS-CoV-2 by real-time reverse transcription PCR (RT-qPCR) 9 days later. All but one mink sampled on the farm were positive for SARS-CoV-2 based on nucleic acid detection from at least one oral, nasal, or rectal swab tested by RT-qPCR (99%). Sequence analysis showed high degrees of similarity between sequences from mink and the two positive farm employees. Epidemiologic and genomic data, including the presence of F486L and N501T mutations believed to arise through mink adaptation, support the hypothesis that the two employees with SARS-CoV-2 nucleic acid detection contracted COVID-19 from mink. However, the specific source of virus introduction onto the farm was not identified. Three companion animals living with mink farm employees and 31 wild animals of six species sampled in the surrounding area were negative for SARS-CoV-2 by RT-qPCR. Results from this investigation support the necessity of a One Health approach to manage the zoonotic spread of SARS-CoV-2 and underscores the critical need for multifaceted public health approaches to prevent the introduction and spread of respiratory viruses on mink farms.
Collapse
Affiliation(s)
- Ria R. Ghai
- U.S. Centers for Disease Control and Prevention, Atlanta, GA 30333, USA; (R.R.G.)
| | - Anne Straily
- U.S. Centers for Disease Control and Prevention, Atlanta, GA 30333, USA; (R.R.G.)
| | - Nora Wineland
- Michigan Department of Agriculture and Rural Development, Lansing, MI 48933, USA
| | - Jennifer Calogero
- Michigan Department of Agriculture and Rural Development, Lansing, MI 48933, USA
| | | | - Kimberly Signs
- Michigan Department of Health and Human Services, Lansing, MI 48909, USA
| | - Melissa Blievernicht
- Michigan Department of Agriculture and Rural Development, Lansing, MI 48933, USA
| | | | | | - Jillian A. Condrey
- U.S. Centers for Disease Control and Prevention, Atlanta, GA 30333, USA; (R.R.G.)
| | | | - Diana Riner
- Michigan Department of Health and Human Services, Lansing, MI 48909, USA
| | - Nancy Barr
- Michigan Department of Agriculture and Rural Development, Lansing, MI 48933, USA
| | - Michele Schalow
- Michigan Department of Agriculture and Rural Development, Lansing, MI 48933, USA
| | - Jarold Goodrich
- Michigan Department of Agriculture and Rural Development, Lansing, MI 48933, USA
| | - Cheryl Collins
- Michigan Department of Agriculture and Rural Development, Lansing, MI 48933, USA
| | - Ausaf Ahmad
- U.S. Centers for Disease Control and Prevention, Atlanta, GA 30333, USA; (R.R.G.)
| | - John Michael Metz
- U.S. Centers for Disease Control and Prevention, Atlanta, GA 30333, USA; (R.R.G.)
| | - Owen Herzegh
- U.S. Centers for Disease Control and Prevention, Atlanta, GA 30333, USA; (R.R.G.)
| | - Kelly Straka
- Michigan Department of Natural Resources, Lansing, MI 48909, USA
| | - Dustin M. Arsnoe
- U.S. Department of Agriculture Animal and Plant Health Inspection Service, Washington, DC 20250, USA
| | - Anthony G. Duffiney
- U.S. Department of Agriculture Animal and Plant Health Inspection Service, Washington, DC 20250, USA
| | - Susan A. Shriner
- U.S. Department of Agriculture Animal and Plant Health Inspection Service, Washington, DC 20250, USA
| | | | - Ann Carpenter
- U.S. Centers for Disease Control and Prevention, Atlanta, GA 30333, USA; (R.R.G.)
| | - Florence Whitehill
- U.S. Centers for Disease Control and Prevention, Atlanta, GA 30333, USA; (R.R.G.)
| | - Natalie M. Wendling
- U.S. Centers for Disease Control and Prevention, Atlanta, GA 30333, USA; (R.R.G.)
| | - Robyn A. Stoddard
- U.S. Centers for Disease Control and Prevention, Atlanta, GA 30333, USA; (R.R.G.)
| | - Adam C. Retchless
- U.S. Centers for Disease Control and Prevention, Atlanta, GA 30333, USA; (R.R.G.)
| | - Anna Uehara
- U.S. Centers for Disease Control and Prevention, Atlanta, GA 30333, USA; (R.R.G.)
| | - Ying Tao
- U.S. Centers for Disease Control and Prevention, Atlanta, GA 30333, USA; (R.R.G.)
| | - Yan Li
- U.S. Centers for Disease Control and Prevention, Atlanta, GA 30333, USA; (R.R.G.)
| | - Jing Zhang
- U.S. Centers for Disease Control and Prevention, Atlanta, GA 30333, USA; (R.R.G.)
| | - Suxiang Tong
- U.S. Centers for Disease Control and Prevention, Atlanta, GA 30333, USA; (R.R.G.)
| | | |
Collapse
|
2
|
Miller MR, Braun E, Ip HS, Tyson GH. Domestic and wild animal samples and diagnostic testing for SARS-CoV-2. Vet Q 2023; 43:1-11. [PMID: 37779468 PMCID: PMC10614713 DOI: 10.1080/01652176.2023.2263864] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2023] [Accepted: 09/21/2023] [Indexed: 10/03/2023] Open
Abstract
From the first cases in 2019, COVID-19 infections caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have resulted in over 6 million human deaths in a worldwide pandemic. SARS-CoV-2 is commonly spread from human to human through close contact and is capable of infecting both humans and animals. Worldwide, there have been over 675 animal outbreaks reported that resulted in over 2000 animal infections including domestic and wild animals. As the role of animal infections in the transmission, pathogenesis, and evolution of SARS-CoV-2 is still unfolding, accurate and reliable animal diagnostic tests are critical to aid in managing both human and animal health. This review highlights key animal samples and the three main diagnostic approaches used for animal testing: PCR, serology, and Next Generation Sequencing. Diagnostic results help inform (often difficult) clinical decision-making, but also possible ways to mitigate spread among pets, food supplies, or wildlife. A One Health approach has been key to monitoring the SARS-CoV-2 pandemic, as consistent human-animal interactions can lead to novel variants. Having multiple animal diagnostic tests for SARS-CoV-2 available is critical to ensure human, animal, and environmental health.
Collapse
Affiliation(s)
- Megan R. Miller
- Center for Veterinary Medicine, U.S. Food and Drug Administration, Laurel, MD, USA
| | - Elias Braun
- Center for Veterinary Medicine, U.S. Food and Drug Administration, Laurel, MD, USA
- School of Veterinary Medicine, University of PA, Philadelphia, PA, USA
| | - Hon S. Ip
- National Wildlife Health Center, U.S. Geological Survey, Madison, WI, USA
| | - Gregory H. Tyson
- Center for Veterinary Medicine, U.S. Food and Drug Administration, Laurel, MD, USA
| |
Collapse
|
3
|
Scholte FEM, Karaaslan E, O’Neal TJ, Sorvillo TE, Genzer SC, Welch SR, Coleman-McCray JD, Spengler JR, Kainulainen MH, Montgomery JM, Pegan SD, Bergeron E, Spiropoulou CF. Vaccination with the Crimean-Congo hemorrhagic fever virus viral replicon vaccine induces NP-based T-cell activation and antibodies possessing Fc-mediated effector functions. Front Cell Infect Microbiol 2023; 13:1233148. [PMID: 37671145 PMCID: PMC10475602 DOI: 10.3389/fcimb.2023.1233148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2023] [Accepted: 07/10/2023] [Indexed: 09/07/2023] Open
Abstract
Crimean-Congo hemorrhagic fever virus (CCHFV; family Nairoviridae) is a tick-borne pathogen that frequently causes lethal disease in humans. CCHFV has a wide geographic distribution, and cases have been reported in Africa, Asia, the Middle East, and Europe. Availability of a safe and efficacious vaccine is critical for restricting outbreaks and preventing disease in endemic countries. We previously developed a virus-like replicon particle (VRP) vaccine that provides complete protection against homologous and heterologous lethal CCHFV challenge in mice after a single dose. However, the immune responses induced by this vaccine are not well characterized, and correlates of protection remain unknown. Here we comprehensively characterized the kinetics of cell-mediated and humoral immune responses in VRP-vaccinated mice, and demonstrate that they predominantly target the nucleoprotein (NP). NP antibodies are not associated with protection through neutralizing activity, but VRP vaccination results in NP antibodies possessing Fc-mediated antibody effector functions, such as complement activation (ADCD) and antibody-mediated cellular phagocytosis (ADCP). This suggests that Fc-mediated effector functions may contribute to this vaccine's efficacy.
Collapse
Affiliation(s)
- F. E. M. Scholte
- Viral Special Pathogens Branch, Division of High-Consequence Pathogens & Pathology, Centers for Disease Control & Prevention, Atlanta, GA, United States
| | - E. Karaaslan
- Viral Special Pathogens Branch, Division of High-Consequence Pathogens & Pathology, Centers for Disease Control & Prevention, Atlanta, GA, United States
- Division of Biomedical Sciences, School of Medicine, University of California, Riverside, Riverside, CA, United States
| | - T. J. O’Neal
- Viral Special Pathogens Branch, Division of High-Consequence Pathogens & Pathology, Centers for Disease Control & Prevention, Atlanta, GA, United States
| | - T. E. Sorvillo
- Viral Special Pathogens Branch, Division of High-Consequence Pathogens & Pathology, Centers for Disease Control & Prevention, Atlanta, GA, United States
| | - S. C. Genzer
- Viral Special Pathogens Branch, Division of High-Consequence Pathogens & Pathology, Centers for Disease Control & Prevention, Atlanta, GA, United States
| | - S. R. Welch
- Viral Special Pathogens Branch, Division of High-Consequence Pathogens & Pathology, Centers for Disease Control & Prevention, Atlanta, GA, United States
| | - J. D. Coleman-McCray
- Viral Special Pathogens Branch, Division of High-Consequence Pathogens & Pathology, Centers for Disease Control & Prevention, Atlanta, GA, United States
| | - J. R. Spengler
- Viral Special Pathogens Branch, Division of High-Consequence Pathogens & Pathology, Centers for Disease Control & Prevention, Atlanta, GA, United States
| | - M. H. Kainulainen
- Viral Special Pathogens Branch, Division of High-Consequence Pathogens & Pathology, Centers for Disease Control & Prevention, Atlanta, GA, United States
| | - J. M. Montgomery
- Viral Special Pathogens Branch, Division of High-Consequence Pathogens & Pathology, Centers for Disease Control & Prevention, Atlanta, GA, United States
| | - S. D. Pegan
- Division of Biomedical Sciences, School of Medicine, University of California, Riverside, Riverside, CA, United States
| | - E. Bergeron
- Viral Special Pathogens Branch, Division of High-Consequence Pathogens & Pathology, Centers for Disease Control & Prevention, Atlanta, GA, United States
| | - C. F. Spiropoulou
- Viral Special Pathogens Branch, Division of High-Consequence Pathogens & Pathology, Centers for Disease Control & Prevention, Atlanta, GA, United States
| |
Collapse
|
4
|
Cossaboom CM, Wendling NM, Lewis NM, Rettler H, Harvey RR, Amman BR, Towner JS, Spengler JR, Erickson R, Burnett C, Young EL, Oakeson K, Carpenter A, Kainulainen MH, Chatterjee P, Flint M, Uehara A, Li Y, Zhang J, Kelleher A, Lynch B, Retchless AC, Tong S, Ahmad A, Bunkley P, Godino C, Herzegh O, Drobeniuc J, Rooney J, Taylor D, Barton Behravesh C. One Health Investigation of SARS-CoV-2 in People and Animals on Multiple Mink Farms in Utah. Viruses 2022; 15:96. [PMID: 36680136 PMCID: PMC9864593 DOI: 10.3390/v15010096] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2022] [Revised: 12/21/2022] [Accepted: 12/23/2022] [Indexed: 12/31/2022] Open
Abstract
From July−November 2020, mink (Neogale vison) on 12 Utah farms experienced an increase in mortality rates due to confirmed SARS-CoV-2 infection. We conducted epidemiologic investigations on six farms to identify the source of virus introduction, track cross-species transmission, and assess viral evolution. Interviews were conducted and specimens were collected from persons living or working on participating farms and from multiple animal species. Swabs and sera were tested by SARS-CoV-2 real-time reverse transcription polymerase chain reaction (rRT-PCR) and serological assays, respectively. Whole genome sequencing was attempted for specimens with cycle threshold values <30. Evidence of SARS-CoV-2 infection was detected by rRT-PCR or serology in ≥1 person, farmed mink, dog, and/or feral cat on each farm. Sequence analysis showed high similarity between mink and human sequences on corresponding farms. On farms sampled at multiple time points, mink tested rRT-PCR positive up to 16 weeks post-onset of increased mortality. Workers likely introduced SARS-CoV-2 to mink, and mink transmitted SARS-CoV-2 to other animal species; mink-to-human transmission was not identified. Our findings provide critical evidence to support interventions to prevent and manage SARS-CoV-2 in people and animals on mink farms and emphasizes the importance of a One Health approach to address emerging zoonoses.
Collapse
Affiliation(s)
- Caitlin M. Cossaboom
- National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
| | - Natalie M. Wendling
- National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
| | - Nathaniel M. Lewis
- Utah Department of Health and Human Services, Salt Lake City, UT 84116, USA
- Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
| | - Hannah Rettler
- Utah Department of Health and Human Services, Salt Lake City, UT 84116, USA
| | - Robert R. Harvey
- Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, Morgantown, WV 26505, USA
| | - Brian R. Amman
- National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
| | - Jonathan S. Towner
- National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
| | - Jessica R. Spengler
- National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
| | - Robert Erickson
- Utah Department of Agriculture and Food, Salt Lake City, UT 84129, USA
| | - Cindy Burnett
- Utah Department of Health and Human Services, Salt Lake City, UT 84116, USA
| | - Erin L. Young
- Utah Public Health Laboratory, Utah Department of Health and Human Services, Salt Lake City, UT 84129, USA
| | - Kelly Oakeson
- Utah Public Health Laboratory, Utah Department of Health and Human Services, Salt Lake City, UT 84129, USA
| | - Ann Carpenter
- National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
| | - Markus H. Kainulainen
- National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
| | - Payel Chatterjee
- National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
| | - Mike Flint
- National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
| | - Anna Uehara
- National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
| | - Yan Li
- National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
| | - Jing Zhang
- National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
| | - Anna Kelleher
- National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
| | - Brian Lynch
- National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
| | - Adam C. Retchless
- National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
| | - Suxiang Tong
- National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
| | - Ausaf Ahmad
- National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
| | - Paige Bunkley
- National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
| | - Claire Godino
- National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
| | - Owen Herzegh
- National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
| | - Jan Drobeniuc
- CDC National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
| | - Jane Rooney
- United States Department of Agriculture, Animal and Plant Health Inspection Service, Veterinary Services, Fort Collins, CO 80526, USA
| | - Dean Taylor
- Utah Department of Agriculture and Food, Salt Lake City, UT 84129, USA
| | - Casey Barton Behravesh
- National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
| |
Collapse
|
5
|
Torio EA, Ressler VT, Kincaid VA, Hurst R, Hall MP, Encell LP, Zimmerman K, Forsyth SK, Rehrauer WM, Accola MA, Hsu CC, Machleidt T, Dart ML. Development of a rapid, simple, and sensitive point-of-care technology platform utilizing ternary NanoLuc. Front Microbiol 2022; 13:970233. [PMID: 36386626 PMCID: PMC9643700 DOI: 10.3389/fmicb.2022.970233] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2022] [Accepted: 10/06/2022] [Indexed: 12/02/2022] Open
Abstract
Point-of-care tests are highly valuable in providing fast results for medical decisions for greater flexibility in patient care. Many diagnostic tests, such as ELISAs, that are commonly used within clinical laboratory settings require trained technicians, laborious workflows, and complex instrumentation hindering their translation into point-of-care applications. Herein, we demonstrate the use of a homogeneous, bioluminescent-based, split reporter platform that enables a simple, sensitive, and rapid method for analyte detection in clinical samples. We developed this point-of-care application using an optimized ternary, split-NanoLuc luciferase reporter system that consists of two small reporter peptides added as appendages to analyte-specific affinity reagents. A bright, stable bioluminescent signal is generated as the affinity reagents bind to the analyte, allowing for proximity-induced complementation between the two reporter peptides and the polypeptide protein, in addition to the furimazine substrate. Through lyophilization of the stabilized reporter system with the formulated substrate, we demonstrate a shelf-stable, all-in-one, add-and-read analyte-detection system for use in complex sample matrices at the point-of-care. We highlight the modularity of this platform using two distinct SARS-CoV-2 model systems: SARS-CoV-2 N-antigen detection for active infections and anti-SARS-CoV-2 antibodies for immunity status detection using chemically conjugated or genetically fused affinity reagents, respectively. This technology provides a simple and standardized method to develop rapid, robust, and sensitive analyte-detection assays with flexible assay formatting making this an ideal platform for research, clinical laboratory, as well as point-of-care applications utilizing a simple handheld luminometer.
Collapse
Affiliation(s)
| | | | | | - Robin Hurst
- Promega Corporation, Madison, WI, United States
| | - Mary P Hall
- Promega Corporation, Madison, WI, United States
| | | | | | | | - William M Rehrauer
- Department of Pathology and Laboratory Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, United States
- University of Wisconsin Hospital and Clinics, Clinical Laboratories, Madison, WI, United States
| | - Molly A Accola
- University of Wisconsin Hospital and Clinics, Clinical Laboratories, Madison, WI, United States
| | | | | | | |
Collapse
|
6
|
Cable J, Fauci A, Dowling WE, Günther S, Bente DA, Yadav PD, Madoff LC, Wang L, Arora RK, Van Kerkhove M, Chu MC, Jaenisch T, Epstein JH, Frost SDW, Bausch DG, Hensley LE, Bergeron É, Sitaras I, Gunn MD, Geisbert TW, Muñoz‐Fontela C, Krammer F, de Wit E, Nordenfelt P, Saphire EO, Gilbert SC, Corbett KS, Branco LM, Baize S, van Doremalen N, Krieger MA, Clemens SAC, Hesselink R, Hartman D. Lessons from the pandemic: Responding to emerging zoonotic viral diseases-a Keystone Symposia report. Ann N Y Acad Sci 2022; 1518:209-225. [PMID: 36183296 PMCID: PMC9538336 DOI: 10.1111/nyas.14898] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The COVID-19 pandemic caught the world largely unprepared, including scientific and policy communities. On April 10-13, 2022, researchers across academia, industry, government, and nonprofit organizations met at the Keystone symposium "Lessons from the Pandemic: Responding to Emerging Zoonotic Viral Diseases" to discuss the successes and challenges of the COVID-19 pandemic and what lessons can be applied moving forward. Speakers focused on experiences not only from the COVID-19 pandemic but also from outbreaks of other pathogens, including the Ebola virus, Lassa virus, and Nipah virus. A general consensus was that investments made during the COVID-19 pandemic in infrastructure, collaborations, laboratory and manufacturing capacity, diagnostics, clinical trial networks, and regulatory enhancements-notably, in low-to-middle income countries-must be maintained and strengthened to enable quick, concerted responses to future threats, especially to zoonotic pathogens.
Collapse
Affiliation(s)
| | - Anthony Fauci
- Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID)National Institutes of Health (NIH)BethesdaMarylandUSA
| | | | - Stephan Günther
- Bernhard Nocht Institute for Tropical Medicine and German Center for Infection ResearchHamburgGermany
| | - Dennis A. Bente
- University of Texas Medical BranchGalveston National LaboratoryGalvestonTexasUSA,Division of Biology and Biological EngineeringCalifornia Institute of TechnologyPasadenaCaliforniaUSA
| | - Pragya Dhruv Yadav
- Indian Council of Medical Research‐National Institute of VirologyPuneIndia
| | - Lawrence C. Madoff
- Department of MedicineUniversity of Massachusetts Chan School of MedicineWorcesterMassachusettsUSA
| | | | - Rahul K. Arora
- Department of Community Health SciencesUniversity of CalgaryCalgaryAlbertaCanada,Institute of Biomedical EngineeringUniversity of OxfordOxfordUK
| | | | - May C. Chu
- Colorado School of Public HealthAnschutz Medical CampusAuroraColoradoUSA
| | - Thomas Jaenisch
- Colorado School of Public HealthAnschutz Medical CampusAuroraColoradoUSA
| | | | | | | | - Lisa E. Hensley
- Partnership for Research on Vaccines and Infectious Diseases in Liberia (PREVAIL)MonroviaLiberia,Division of Clinical ResearchNational Institute of Allergy and Infectious DiseasesBethesdaMarylandUSA
| | - Éric Bergeron
- Viral Special Pathogens Branch, Division of High‐Consequence Pathogens and PathologyCenters for Disease Control and PreventionAtlantaGeorgiaUSA
| | - Ioannis Sitaras
- W. Harry Feinstone Department of Molecular Microbiology and ImmunologyJohns Hopkins Bloomberg School of Public HealthBaltimoreMarylandUSA
| | - Michael D. Gunn
- Department of MedicineDuke University Medical CenterDurhamNorth CarolinaUSA
| | - Thomas W. Geisbert
- University of ManitobaWinnipegManitobaCanada,Galveston National Laboratory and Department of Microbiology and ImmunologyUniversity of Texas Medical BranchGalvestonTexasUSA
| | - César Muñoz‐Fontela
- Bernhard Nocht Institute for Tropical Medicine and German Center for Infection ResearchHamburgGermany
| | - Florian Krammer
- Department of Microbiology and Department of PathologyIcahn School of Medicine at Mount SinaiNew YorkNew YorkUSA
| | - Emmie de Wit
- Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious DiseasesNational Institutes of HealthHamiltonMontanaUSA
| | - Pontus Nordenfelt
- Department of Clinical Sciences Lund, Infection Medicine, Faculty of MedicineLund UniversityLundSweden
| | - Erica Ollmann Saphire
- Center for Infectious Disease and Vaccine ResearchLa Jolla Institute for ImmunologyLa JollaCaliforniaUSA
| | - Sarah C. Gilbert
- Pandemic Sciences Institute, Nuffield Department of MedicineUniversity of OxfordOxfordUK
| | - Kizzmekia S. Corbett
- Department of Immunology and Infectious DiseasesHarvard T.H. Chan School of Public HealthBostonMassachusettsUSA
| | | | - Sylvain Baize
- Unité de Biologie des Infections Virales EmergentesInstitut PasteurLyonFrance,Centre International de Recherche en Infectiologie (CIRI)LyonFrance,INSERM, Ecole Normale Supérieure de LyonUniversité de LyonLyonFrance
| | - Neeltje van Doremalen
- Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious DiseasesNational Institutes of HealthHamiltonMontanaUSA
| | - Marco A. Krieger
- Laboratory for Applied Science and Technology in Health, Carlos Chagas InstituteOswaldo Cruz Foundation ‐ ParanáCuritibaBrazil,Integrated Translational Program in Chagas Disease from Fiocruz (Fio‐Chagas)Oswaldo Cruz Foundation ‐ Rio de JaneiroRio de JaneiroBrazil
| | - Sue Ann Costa Clemens
- Oxford Vaccine GroupOxford UniversityOxfordUK,Institute for Global HealthUniversity of SienaSienaItaly
| | - Renske Hesselink
- Coalition for Epidemic Preparedness Innovations (CEPI)OsloNorway
| | - Dan Hartman
- Bill & Melinda Gates FoundationSeattleWashingtonUSA
| |
Collapse
|
7
|
GPS Tracking of Free-Roaming Cats (Felis catus) on SARS-CoV-2-Infected Mink Farms in Utah. Viruses 2022; 14:v14102131. [PMID: 36298686 PMCID: PMC9611678 DOI: 10.3390/v14102131] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2022] [Revised: 09/19/2022] [Accepted: 09/23/2022] [Indexed: 11/20/2022] Open
Abstract
Zoonotic transmission of SARS-CoV-2 from infected humans to other animals has been documented around the world, most notably in mink farming operations in Europe and the United States. Outbreaks of SARS-CoV-2 on Utah mink farms began in late July 2020 and resulted in high mink mortality. An investigation of these outbreaks revealed active and past SARS-CoV-2 infections in free-roaming and in feral cats living on or near several mink farms. Cats were captured using live traps, were sampled, fitted with GPS collars, and released on the farms. GPS tracking of these cats show they made frequent visits to mink sheds, moved freely around the affected farms, and visited surrounding residential properties and neighborhoods on multiple occasions, making them potential low risk vectors of additional SARS-CoV-2 spread in local communities.
Collapse
|
8
|
Gwyn S, Abubakar A, Akinmulero O, Bergeron E, Blessing UN, Chaitram J, Coughlin MM, Dawurung AB, Dickson FN, Esiekpe M, Evbuomwan E, Greby SM, Iriemenam NC, Kainulainen MH, Naanpoen TA, Napoloen L, Odoh I, Okoye M, Olaleye T, Schuh AJ, Owen SM, Samuel A, Martin DL. Performance of SARS-CoV-2 Antigens in a Multiplex Bead Assay for Integrated Serological Surveillance of Neglected Tropical and Other Diseases. Am J Trop Med Hyg 2022; 107:260-267. [PMID: 35895418 PMCID: PMC9393470 DOI: 10.4269/ajtmh.22-0078] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2022] [Accepted: 03/26/2022] [Indexed: 11/21/2022] Open
Abstract
Serosurveillance can provide estimates of population-level exposure to infectious pathogens and has been used extensively during the COVID-19 pandemic. Simultaneous, serological testing for multiple pathogens can be done using bead-based immunoassays to add value to disease-specific serosurveys. We conducted a validation of four SARS-CoV-2 antigens-full-length spike protein, two receptor binding domain proteins, and the nucleocapsid protein-on our existing multiplex bead assay (MBA) for enteric diseases, malaria, and vaccine preventable diseases. After determining the optimal conditions for coupling the antigens to microsphere beads, the sensitivity and specificity of the assay were determined on two instruments (Luminex-200 and MAGPIX) when testing singly (monoplex) versus combined (multiplex). Sensitivity was assessed using plasma from 87 real-time reverse transcription polymerase chain reaction (rRT-PCR) positive persons collected in March-May of 2020 and ranged from 94.3% to 96.6% for the different testing conditions. Specificity was assessed using 98 plasma specimens collected prior to December 2019 and plasma from 19 rRT-PCR negative persons and ranged from 97.4% to 100%. The positive percent agreement was 93.8% to 97.9% using 48 specimens collected > 21 days post-symptom onset, while the negative percent agreement was ≥ 99% for all antigens. Test performance was similar using monoplex or multiplex testing. Integrating SARS-CoV-2 serology with other diseases of public health interest could add significant value to public health programs that have suffered severe programmatic setbacks during the COVID-19 pandemic.
Collapse
Affiliation(s)
- Sarah Gwyn
- Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia
| | | | | | - Eric Bergeron
- Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia
| | | | - Jasmine Chaitram
- Division of Laboratory Systems, Centers for Disease Control and Prevention, Atlanta, Georgia
| | - Melissa M. Coughlin
- Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia
| | | | | | | | | | - Stacie M. Greby
- Division of Global HIV and TB, Centers for Disease Control and Prevention, Abuja, Nigeria
| | - Nnaemeka C. Iriemenam
- Division of Global HIV and TB, Centers for Disease Control and Prevention, Abuja, Nigeria
| | - Markus H. Kainulainen
- Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia
| | | | | | | | - McPaul Okoye
- Division of Global HIV and TB, Centers for Disease Control and Prevention, Abuja, Nigeria
| | | | - Amy J. Schuh
- Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia
| | - S. Michele Owen
- National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, Atlanta, Georgia
| | | | - Diana L. Martin
- Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia
| |
Collapse
|
9
|
Kincaid VA, Wang H, Sondgeroth CA, Torio EA, Ressler VT, Fitzgerald C, Hall MP, Hurst R, Wood MG, Gilden JK, Kirkland TA, Lazar D, Chia-Chang H, Encell LP, Machleidt T, Zhou W, Dart ML. Simple, Rapid Chemical Labeling and Screening of Antibodies with Luminescent Peptides. ACS Chem Biol 2022; 17:2179-2187. [PMID: 35862857 PMCID: PMC9396617 DOI: 10.1021/acschembio.2c00306] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/04/2022]
Abstract
![]()
Sensitive and selective detection assays are essential
for the
accurate measurement of analytes in both clinical and research laboratories.
Immunoassays that rely on nonoverlapping antibodies directed against
the same target analyte (e.g., sandwich enzyme-linked immunosorbent
assays (ELISAs)) are commonly used molecular detection technologies.
Use of split enzyme reporters has simplified the workflow for these
traditionally complex assays. However, identifying functional antibody
pairs for a given target analyte can be cumbersome, as it generally
involves generating and screening panels of antibodies conjugated
to reporters. Accordingly, we sought a faster and easier reporter
conjugation strategy to streamline antibody screening. We describe
here the development of such a method that is based on an optimized
ternary NanoLuc luciferase. This bioluminescence complementation system
is comprised of a reagent-based thermally stable polypeptide (LgTrip)
and two small peptide tags (β9 and β10) with lysine-reactive
handles for direct conjugation onto antibodies. These reagents enable
fast, single-step, wash-free antibody labeling and sensitive functional
screening. Simplicity, speed, and utility of the one-pot labeling
technology are demonstrated in screening antibody pairs for the analyte
interleukin-4. The screen resulted in the rapid development of a sensitive
homogeneous immunoassay for this clinically relevant cytokine.
Collapse
Affiliation(s)
| | - Hui Wang
- Promega Biosciences LLC, San Luis Obispo, California 93401, United States
| | | | - Emily A Torio
- Promega Corporation, Madison, Wisconsin 53711, United States
| | | | - Connor Fitzgerald
- Promega Biosciences LLC, San Luis Obispo, California 93401, United States
| | - Mary P Hall
- Promega Corporation, Madison, Wisconsin 53711, United States
| | - Robin Hurst
- Promega Corporation, Madison, Wisconsin 53711, United States
| | - Monika G Wood
- Promega Corporation, Madison, Wisconsin 53711, United States
| | - Julia K Gilden
- Promega Corporation, Madison, Wisconsin 53711, United States
| | - Thomas A Kirkland
- Promega Biosciences LLC, San Luis Obispo, California 93401, United States
| | - Dan Lazar
- Promega Corporation, Madison, Wisconsin 53711, United States
| | - Hsu Chia-Chang
- Promega Corporation, Madison, Wisconsin 53711, United States
| | - Lance P Encell
- Promega Corporation, Madison, Wisconsin 53711, United States
| | | | - Wenhui Zhou
- Promega Biosciences LLC, San Luis Obispo, California 93401, United States
| | - Melanie L Dart
- Promega Corporation, Madison, Wisconsin 53711, United States
| |
Collapse
|
10
|
Mitchell KF, Carlson CM, Nace D, Wakeman BS, Drobeniuc J, Niemeyer GP, Werner B, Hoffmaster AR, Satheshkumar PS, Schuh AJ, Udhayakumar V, Rogier E. Evaluation of a Multiplex Bead Assay against Single-Target Assays for Detection of IgG Antibodies to SARS-CoV-2. Microbiol Spectr 2022; 10:e0105422. [PMID: 35647696 PMCID: PMC9241621 DOI: 10.1128/spectrum.01054-22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2022] [Accepted: 05/10/2022] [Indexed: 11/20/2022] Open
Abstract
Serological assays for SARS-CoV-2 antibodies must be validated for performance with a large panel of clinical specimens. Most existing assays utilize a single antigen target and may be subject to reduced diagnostic specificity. This study evaluated a multiplex assay that detects antibodies to three SARS-CoV-2 targets. Human serum specimens (n = 323) with known previous SARS-CoV-2 exposure status were tested on a commercially available multiplex bead assay (MBA) measuring IgG to SARS-CoV-2 spike protein receptor-binding domain (RBD), nucleocapsid protein (NP), and RBD/NP fusion antigens. Assay performance was evaluated against reverse transcriptase PCR (RT-PCR) results and also compared with test results for two single-target commercial assays. The MBA had a diagnostic sensitivity of 89.8% and a specificity of 100%, with serum collection at >28 days following COVID-19 symptom onset showing the highest seropositivity rates (sensitivity: 94.7%). The MBA performed comparably to single-target assays with the ability to detect IgG against specific antigen targets, with 19 (5.9%) discrepant specimens compared to the NP IgG assay and 12 (3.7%) compared to the S1 RBD IgG assay (kappa coefficients 0.92 and 0.88 compared to NP IgG and S1 RBD IgG assays, respectively. These findings highlight inherent advantages of using a SARS-CoV-2 serological test with multiple antigen targets; specifically, the ability to detect IgG against RBD and NP antigens simultaneously. In particular, the 100.0% diagnostic specificity exhibited by the MBA in this study is important for its implementation in populations with low SARS-CoV-2 seroprevalence or where background antibody reactivity to SARS-CoV-2 antigens has been detected. IMPORTANCE Reporting of SARS-CoV-2 infections through nucleic acid or antigen based diagnostic tests severely underestimates the true burden of exposure in a population. Serological data assaying for antibodies against SARS-CoV-2 antigens offers an alternative source of data to estimate population exposure, but most current immunoassays only include a single target for antibody detection. This report outlines a direct comparison of a multiplex bead assay to two other commercial single-target assays in their ability to detect IgG against SARS-CoV-2 antigens. Against a well-defined panel of 323 serum specimens, diagnostic sensitivity and specificity were very high for the multiplex assay, with strong agreement in IgG detection for single targets compared to the single-target assays. Collection of more data for individual- and population-level seroprofiles allows further investigation into more accurate exposure estimates and research into the determinants of infection and convalescent responses.
Collapse
Affiliation(s)
- Kaitlin F. Mitchell
- Laboratory Leadership Service assigned to Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Christina M. Carlson
- Malaria Branch, Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Douglas Nace
- Malaria Branch, Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Brian S. Wakeman
- Malaria Branch, Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
- Williams Consulting, LLC, Baltimore, Maryland, USA
| | - Jan Drobeniuc
- Laboratory Task Force, COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Glenn P. Niemeyer
- Laboratory Task Force, COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Bonnie Werner
- Laboratory Task Force, COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Alex R. Hoffmaster
- Laboratory Task Force, COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | | | - Amy J. Schuh
- Laboratory Task Force, COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Venkatachalam Udhayakumar
- Malaria Branch, Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Eric Rogier
- Malaria Branch, Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| |
Collapse
|
11
|
Adamson H, Ajayi MO, Gilroy KE, McPherson MJ, Tomlinson DC, Jeuken LJC. Rapid Quantification of C. difficile Glutamate Dehydrogenase and Toxin B (TcdB) with a NanoBiT Split-Luciferase Assay. Anal Chem 2022; 94:8156-8163. [PMID: 35634999 PMCID: PMC9201815 DOI: 10.1021/acs.analchem.1c05206] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
![]()
C. difficile infection (CDI) is a leading healthcare-associated
infection with a high morbidity and mortality and is a financial burden.
No current standalone point-of-care test (POCT) is sufficient for
the identification of true CDI over a disease-free carriage of C. difficile, so one is urgently required to ensure timely,
appropriate treatment. Here, two types of binding proteins, Affimers
and nanobodies, targeting two C. difficile biomarkers,
glutamate dehydrogenase (GDH) and toxin B (TcdB), are combined in
NanoBiT (NanoLuc Binary Technology) split-luciferase assays. The assays
were optimized and their performance controlling parameters were examined.
The 44 fM limit of detection (LoD), 4–5 log range and 1300-fold
signal gain of the TcdB assay in buffer is the best observed for a
NanoBiT assay to date. In the stool sample matrix, the GDH and TcdB
assay sensitivity (LoD = 4.5 and 2 pM, respectively) and time to result
(32 min) are similar to a current, commercial lateral flow POCT, but
the NanoBit assay has no wash steps, detects clinically relevant TcdB
over TcdA, and is quantitative. Development of the assay into a POCT
may drive sensitivity further and offer an urgently needed ultrasensitive
TcdB test for the rapid diagnosis of true CDI. The NanoBiTBiP (NanoBiT
with Binding Proteins) system offers advantages over NanoBiT assays
with antibodies as binding elements in terms of ease of production
and assay performance. We expect this methodology and approach to
be generally applicable to other biomarkers.
Collapse
Affiliation(s)
- Hope Adamson
- School of Biomedical Sciences and Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds, LS2 9JT, United Kingdom
| | - Modupe O. Ajayi
- School of Molecular and Cellular Biology and Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds, LS2 9JT, United Kingdom
| | - Kate E. Gilroy
- School of Molecular and Cellular Biology and Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds, LS2 9JT, United Kingdom
| | - Michael J. McPherson
- School of Molecular and Cellular Biology and Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds, LS2 9JT, United Kingdom
| | - Darren C. Tomlinson
- School of Molecular and Cellular Biology and Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds, LS2 9JT, United Kingdom
| | - Lars J. C. Jeuken
- School of Biomedical Sciences and Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds, LS2 9JT, United Kingdom
- Leiden Institute of Chemistry, Leiden University, PC Box 9502, 2300 RA, Leiden, The Netherlands
| |
Collapse
|
12
|
Wendling NM, Carpenter A, Liew A, Ghai RR, Gallardo-Romero N, Stoddard RA, Tao Y, Zhang J, Retchless AC, Ahmad A, Bunkley P, Godino C, Mauldin MR, Varela K, Ritter JM, Hennebelle J, Feldpausch A, Gabel J, Kainulainen MH, Herzegh O, Tong S, Spengler JR, Barton Behravesh C. Transmission of SARS-CoV-2 Delta variant (B.1.617.2) from a fully vaccinated human to a canine in Georgia, July 2021. Zoonoses Public Health 2022; 69:587-592. [PMID: 35426241 PMCID: PMC9115446 DOI: 10.1111/zph.12944] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2022] [Revised: 02/16/2022] [Accepted: 03/20/2022] [Indexed: 01/09/2023]
Abstract
SARS‐CoV‐2 infection has been described in a wide range of species, including domestic animals such as dogs and cats. Illness in dogs is usually self‐limiting, and further diagnostics may not be pursued if clinical signs resolve or they respond to empirical treatment. As new variants emerge, the clinical presentation and role in transmission may vary in animals. This report highlights different clinical presentations and immunological responses in two SARS‐CoV‐2 Delta‐variant‐positive dogs with similar exposure to the same fully vaccinated human with a SARS‐CoV‐2 infection and emphasizes the need for active surveillance and additional One Health research on SARS‐CoV‐2 variant infections in companion animals and other species.
Collapse
Affiliation(s)
| | - Ann Carpenter
- Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Amanda Liew
- Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Ria R Ghai
- Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | | | - Robyn A Stoddard
- Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Ying Tao
- Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Jing Zhang
- Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Adam C Retchless
- Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Ausaf Ahmad
- Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Paige Bunkley
- Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Claire Godino
- Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | | | - Kate Varela
- Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Jana M Ritter
- Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | | | | | - Julie Gabel
- Georgia Department of Public Health, Atlanta, Georgia, USA
| | | | - Owen Herzegh
- Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | - Suxiang Tong
- Centers for Disease Control and Prevention, Atlanta, Georgia, USA
| | | | | |
Collapse
|